MedPath

Closed-loop Medtronic 780G System in Youth With Type 1 Diabetes

Recruiting
Conditions
Type 1 Diabetes
Child, Only
Registration Number
NCT05908708
Lead Sponsor
Sheba Medical Center
Brief Summary

The goal of this observational study is to describe data on Israeli children and youth using the 780G system including data regarding glycemic control parameters, various questionnaires, sleep data, bioimpedance measures, and dietary parameters. The main questions it aims to answer are: • whether the 780G system will improve glycemic control • whether the psychosocial aspects will improve. Participants will be followed once connected to 780G, at baseline, one, three, and six months after the connection.

Detailed Description

Patients and Methods:

The study population will include individuals with type 1 diabetes ages 7-18 years who are managed by the pediatric diabetes teams from the AWeSoMe Study Group (five pediatric diabetes multidisciplinary clinics in Israel; Dana-Dwek Children's Hospital, Edmond and Lily Safra Children's Hospital, Maccabi National Juvenile Diabetes Center, Shamir Medical Center and Wolfson Medical Center) and who chose to purchase 780G out-of-pocket as part of their diabetes care, or are eligible according to the updated Israeli basket to receive it. The decision to use 780G will be made prior to and independent of their entrance to the study, and will be based on preferences of the patients and their parents.

Study design:

A prospective multi-center study (AWeSoMe Study Group) of type 1 diabetes patients using the closed-loop Medtronic 780G system as compared to their previous treatment regimen.

Data will be collected at 4 timepoints: baseline (at initiation of 780G system), after 1 month, three months and 6 months of the closed-loop Medtronic 780G system usage.

Data collection:

All the data collected are available for healthcare providers (doctors, nurses and dieticians) as part of the routine diabetes clinic visit. The information retrieved from the medical files will include sociodemographic characteristics (current age, sex, socioeconomic position by home address, parent's education level, marital status of parents), anthropometric parameters (height, weight and body mass index), pubertal status, physical activity levels and diabetes-related characteristics. Diabetes-related characteristics: age at diagnosis, autoimmune co-morbidities (thyroid disease and Celiac), glycated hemoglobin (HbA1c) and acute complications (severe hypoglycemic episodes and DKA). Insulin pump and CGM downloaded data retrieved during the 2 weeks prior to the clinic visit: mode of insulin therapy (previous and current), total daily insulin dose (Units/kg/day), total daily carbohydrates (grams/day) and CGM metrics. CGM metrics will include: percent time CGM active, mean glucose level, standard deviation (SD), coefficient of variability (CV), time in range (TIR), time above range (TAR), time below range (TBR) and glucose management indicator (GMI). Closed-loop Medtronic 780G system user evaluation: reason for switching from conventional treatment to closed-loop, automode system exits and patient's/parent's perception of closed-loop system.

In addition to the data mentioned above the following data will be collected:

1. Questionnaires for the:

1. Patients - the quality of life, anxiety, fear of hypoglycemia - child, diabetes management, and nutrition knowledge in diabetes. All of the questionnaires are validated and were translated into Hebrew using the globally-accepted linguistic validation procedure.

2. Parents - the quality of life, fear of hypoglycemia - parent, diabetes management, sleep quality, and nutrition knowledge in diabetes. All of the questionnaires are validated and were translated into Hebrew using the globally-accepted linguistic validation procedure.

2. Bioimpedance parameters

3. Diet - nutrition evaluation through 3-daily diet notes

4. Sleep - sleep evaluation through parents' 3-daily sleep diaries

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria

Diagnosis of type 1 diabetes Diabetes duration ≥ 6 months Routine attendance at clinic visits Initiation of 780G system usage

Exclusion Criteria

Children under the age of 1 year Children without 780G system

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system0,6 months

Change in time spent in range (70-180 mg/dL) from baseline to six months of closed-loop Medtronic 780G system

Secondary Outcome Measures
NameTimeMethod
Quality of life - child as assessed by a questionnaire0, 6 months

Change in quality of life - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 5, max score 100; the higher the score, the better quality of life.

Fear of hypoglycemia - child as assessed by a questionnaire0, 6 months

Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.

Diabetes management - child as assessed by a questionnaire0, 6 months

Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.

Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system0, 6 months

Change in time spent below range (≤ 70 mg/dL and ≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system

Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system0, 6 months

Delta time spent above range (\> 250 mg/dL) baseline to six months of closed-loop Medtronic 780G system

Quality of life - parent as assessed by a questionnaire0, 6 months

Change in quality of life - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 37, max score 185; the higher the score, the better quality of life.

Nutrition diaries as assessed by a dietician0, 6 months

Change in carbohydrates grams - baseline to 6 months. Assessment of carbohydrates in grams by a certified pediatric nutritionist.

Trait anxiety - child as assessed by a questionnaire0, 6 months

Change in trait anxiety - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 80; the higher the score, the higher the anxiety.

HbA1c as assessed from point-of-care clinic visit0, 6 months

Change in HbA1c from baseline to six months of closed-loop Medtronic 780G system

Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system0, 6 months

Change in time spent below range (≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system

Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system0, 6 months

Change in time spent above range (\> 180 mg/dL) baseline to six months of closed-loop Medtronic 780G system

Fear of hypoglycemia - parent as assessed by a questionnaire0, 6 months

Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.

Diabetes management - parent as assessed by a questionnaire0, 6 months

Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.

Sleep quality as assessed by a questionnaire0, 6 months

Change in sleep quality - baseline to 6 months, as assessed by a validated questionnaire, as cited in the Reference section.

Trial Locations

Locations (1)

Sheba Medical Center

🇮🇱

Ramat Gan, Please Select, Israel

© Copyright 2025. All Rights Reserved by MedPath